Is Aptamer Group (LON: APTA) finally seeing sustained pharma traction with its Optimer platform?

Aptamer Group plc (LON: APTA) has strengthened its commercial momentum in FY26 with two new contract wins valued at £192,000, increasing its signed order book to £1.95 million with seven months remaining in the financial year. The developer of synthetic binders continues to secure repeat business from top-tier global pharmaceutical companies, including a fourth successive engagement with a top five global pharma firm. These contracts reflect growing validation for its proprietary Optimer platform in advanced diagnostic and therapeutic applications where traditional antibodies fall short.

The company’s recent commercial progress is accompanied by continued investor interest. As of 14 November 2025, shares of Aptamer Group plc were trading at 0.95 GBX, following an intraday open of 1.03 GBX. The bid-offer spread stood at 0.90/1.00 GBX, suggesting moderate liquidity and growing institutional attention. The stock’s one-year chart shows a significant upward trend beginning in late August, with the share price moving from below 0.30 GBX to over 1.30 GBX by September before settling into a consolidation phase.

How do the latest contracts enhance commercial validation for Aptamer’s IP-rich model?

The newly secured contracts demonstrate not just volume but also strategic value. One of the deals, valued at £102,000, comes from a returning top five global pharmaceutical company. This is the fourth engagement between the two firms, aimed at providing Optimer binders for enhanced neurological bioanalysis. The repeated selection of Aptamer’s technology indicates confidence in its ability to outperform antibody-based solutions in critical research settings.

The second agreement, worth £90,000, marks a new customer relationship. It focuses on acute myeloid leukaemia (AML), with Optimers to be used as diagnostic tools and to support future therapeutic development. This extends Aptamer Group plc’s footprint in the oncology segment, particularly in high-value clinical and diagnostic programs.

Both contracts are structured as fee-for-service engagements, with Aptamer Group plc retaining full intellectual property ownership of the binders. This model allows the company to generate near-term working capital while continuing to build a long-term licensing and royalty revenue stream. These principles have become a recurring theme across its recent contract portfolio.

How has the contract pipeline evolved and how does it compare with previous financial years?

The cumulative contract value of £1.95 million signed so far in FY26 compares favorably with £1.2 million signed during the same period last year, representing a 62 percent year-on-year increase. This uptick in revenue visibility includes deals with multiple top five and top ten pharmaceutical companies, covering applications in neurology, oncology, radiopharmaceuticals, and drug target validation.

Aptamer Group plc’s recently disclosed commercial engagements include a £617,000 contract with a top five pharmaceutical partner signed on 4 November 2025. This deal involves the development of binders for three separate targets and includes ELISA assay support. According to management, the agreement stemmed from earlier projects in which Optimers outperformed conventional antibody tools, giving rise to an expanded multi-target program.

Additional deals include a £112,000 contract with a top ten pharmaceutical client for a drug target extension, and a £360,000 engagement with a top three pharmaceutical partner involving radiopharmaceutical therapeutic development. Altogether, these partnerships highlight the increasing versatility and scalability of the Optimer platform in diverse therapeutic modalities.

What signals are investors drawing from Aptamer’s stock performance and pharma traction?

The sharp rally in Aptamer Group plc’s stock price between August and September 2025 coincided with several large contract announcements, including the £617,000 top five pharma deal. Since then, the price has consolidated within the 0.90 to 1.00 GBX range, supported by repeated commercial updates and growing pipeline visibility. Institutional sentiment appears to be cautiously optimistic. Analysts tracking the stock believe the current valuation already reflects expectations of further revenue growth but remains conservative compared to the long-term royalty potential of the Optimer platform.

With trading volume and deal frequency increasing, Aptamer’s visibility on the AIM market has improved, especially among investors seeking early-stage, IP-heavy life science platforms with scalable licensing prospects. The repeated engagements with pharmaceutical giants provide reassurance about the platform’s utility in regulated, high-performance settings.

What strategic levers could help Aptamer Group plc expand beyond fee-for-service contracts?

Management at Aptamer Group plc is focused on converting scientific validation into long-term revenue streams. The company retains all intellectual property rights for binders developed under contract, giving it strategic leverage for downstream licensing or clinical co-development partnerships. This IP-centric strategy mirrors models used by successful peers such as Bicycle Therapeutics and PeptiDream, which have transitioned from platform validation to equity-based partnerships and out-licensing of assets.

The company also reported that after signing £0.9 million in deals since its last update, the qualified pipeline has now been replenished to £2.9 million. This indicates continued demand from pharmaceutical and biotechnology companies, especially those working on next-generation therapeutics and diagnostics where specificity, reproducibility, and scalability are critical.

Going forward, investors will be watching for several key signals. These include the conversion of pipeline deals into binding contracts, new therapeutic-stage collaborations beyond radiopharmaceuticals, and updates on how Optimers are being deployed in downstream clinical workflows. In particular, the company’s ability to transition reagent-phase engagements into therapeutic partnerships—while retaining IP—will be a determining factor in how analysts model its medium- to long-term revenue profile.

What institutional confidence trends are emerging around the Optimer platform?

Aptamer Group plc’s repeat business with top-tier pharmaceutical clients is perhaps the most consistent indicator of institutional confidence. Pharmaceutical developers that routinely invest in US$100 million-plus clinical pipelines continue to engage Aptamer’s services across multiple stages of drug development. According to the company, this is a direct outcome of the Optimer platform’s consistent technical performance, validated in proof-of-concept and bioanalytical programs.

The shift from reagent tools to therapeutic binders is already underway, as shown by the group’s recent contract progression with a top three pharmaceutical firm. This radiopharmaceutical engagement began with a reagent project and has now advanced to development of therapeutic candidates. Aptamer Group plc sees this as a blueprint for future relationships: start with a focused technical problem, prove platform value, and expand into revenue-rich co-development paths.

Aptamer’s approach positions it not merely as a service provider but as a strategic technology partner with potential to participate in revenue derived from marketed products, pending success of clinical programs using Optimer binders.

What are the key takeaways from Aptamer Group plc’s latest contract wins and FY26 order update?

• Aptamer Group plc (LON: APTA) has secured £1.95 million in binding FY26 contracts with seven months remaining in the financial year.

• The new deals include a £102,000 fourth-consecutive contract with a top five global pharmaceutical firm focused on neurological bioanalysis.

• A separate £90,000 contract with a new customer targets acute myeloid leukaemia diagnostics, expanding Aptamer’s oncology footprint.

• The Optimer platform continues to generate repeat business across neurology, oncology, and radiopharmaceuticals, validating technical superiority over traditional antibodies.

• All Optimers developed under contract remain fully owned by Aptamer Group plc, reinforcing its long-term licensing and royalty strategy.

• A recent £617,000 deal with a top five pharma partner highlights the company’s evolution from proof-of-concept to multi-target therapeutic development.

• The company’s order book has grown by 62 percent year-on-year compared to the same period in FY25, with contract conversion accelerating.

• The replenished deal pipeline of £2.9 million signals strong ongoing demand for the Optimer platform across global pharmaceutical and biotech clients.

• Shares of Aptamer Group plc are consolidating near 0.95 GBX following a major rally earlier in the year, with cautious optimism seen among institutional investors.

• Management expects full-year revenues to materially exceed FY25, driven by continued commercial momentum and IP-based value creation.